These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27120611)

  • 1. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
    Nie J; Liu Y; Huang W; Wang Y
    Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment and evaluation of a triple-color human papillomavirus pseudovirion neutralization assay].
    Wei SP; Fan F; Chen J; Liu XL; Yang YR; Wang ZP; Song S; Li ZH; Wei MX; Wang DN; Li SW; Xia NS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1039-1044. PubMed ID: 30392324
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of a triple-color pseudovirion-based neutralization assay for immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
    Gao S; Zhao D; Feng C; Kou Y; Lu J; Luo C; Li X; Wang Y; Xie L
    J Med Virol; 2024 Aug; 96(8):e29859. PubMed ID: 39145587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
    Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
    Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT
    Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
    Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
    Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
    Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
    Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.
    Quang C; Chung AW; Kemp TJ; Ratu T; Tuivaga E; Russell FM; Licciardi PV; Toh ZQ
    J Med Virol; 2024 Jun; 96(6):e29732. PubMed ID: 38874202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons.
    Nie J; Huang W; Wu X; Wang Y
    J Med Virol; 2014 Sep; 86(9):1542-55. PubMed ID: 24895216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
    Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
    Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
    Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
    Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.
    Schellenbacher C; Shafti-Keramat S; Huber B; Fink D; Brandt S; Kirnbauer R
    Virology; 2015 Dec; 486():284-90. PubMed ID: 26519597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.